A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

• Status: Recruiting
• Trial end date: 2026-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ImmuneOncia Therapeutics Inc.

Criteria

Inclusion Criteria:

1. ENKTL diagnosis;

• Histologically confirmed diagnosed with extranodal NK/T-cell lymphoma, nasal type

• At least 1 previous line of systemic therapy

• Documented disease progression of last therapy

2. Adult age(as defined by respective country)

3. The nature of the study and voluntarily sign an ICF

4. ECOG 0 or1

5. Adequate hematologic function, hepatic function, and renal function

Exclusion Criteria:

1. Previously treated with an anti-PD-L1 or anti-PD-1 antibody

2. Known presence of symptomatic CNS metastases

3. Prior allogeneic HSCT or solid organ transplantation

4. Any active autoimmune disease or a documented history of autoimmune disease

5. Apparent active or latent TB and known viral infection with hepatitis B virus or hepatitis C virus

6. Pregnant or lactating